本研究的主要目的是比較食道癌受試者接受 nivolumab 與 ipilimumab 或 nivolumab 聯合 fluorouracil 加 cisplatin 對比 fluorouracil 加 cisplatin 後的整體存活時間或無疾病惡化存活時間
適應症：Various Advanced Cancer
收案條件
納入條件
- Must have histologically confirmed squamous cell carcinoma or adenosquamous cell carcinoma of esophagus
- Male or Female at least 18 years of age
- Must have esophageal cancer that cannot be operated on, or treated with definitive chemoradiation with curative intent, that is advanced, reoccurring or has spread out
- Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work
- Must agree to provide tumor tissue sample, either from a previous surgery or biopsy within 6 months or fresh, prior to the start of treatment in this study
排除條件
- Presence of tumor cells in the brain or spinal cord which are symptomatic or require treatment
- Active known or suspected autoimmune disease
- Any serious or uncontrolled medical disorder or active infection
- Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
- Any positive test result for hepatitis B or C indicating acute or chronic infection and/or detectable virus
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。